Nexavar

Description

Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have previously received background treatment with interferon-alpha or interleukin-2 or who are not eligible for such treatment. Hepatocellular carcinoma (HCC)
Nexavar is indicated for the treatment of patients with hepatocellular carcinoma. Differentiated Thyroid Cancer (DTC)

Nexavar is indicated for the treatment of patients with locally advanced or metastatic, progressive, differentiated (papillary/follicular/Hurthl cell) thyroid cancer refractory to radioactive iodine treatment.

Active ingredient: sorafenib

Prescription medicine.